bosentan anhydrous has been researched along with Cirrhosis, Liver in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatano, M; Imamura, T; Kinugawa, K; Komuro, I; Maki, H; Muraoka, H; Yao, A | 1 |
| Vinken, M | 1 |
| Chuang, CL; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Lin, TY; Wang, SS | 1 |
| Chang, YK; Choi, DE; Choi, H; Jeong, JY; Lee, KW; Na, KR | 1 |
| Baumelou, A; Izzedine, H | 1 |
| Cavasin, MA; Chapo, J; Peng, Y; Pitts, K; Plato, CF; Sandoval, J; Semus, H | 1 |
| Alber, H; Colleselli, D; Kähler, CM; Molnar, C; Vogel, W | 1 |
| Graziadei, IW; Hinterhuber, L; Jaschke, W; Kähler, CM; Vogel, W | 1 |
| Eller, P; Fuschelberger, R; Grander, W; Tilg, H | 1 |
| Gerbes, AL; Gülberg, V; Neuhofer, W | 1 |
| Barth, F; Dufour, JF; Gerber, PJ; Nicod, LP; Reichen, J | 1 |
| Ashfaq, M; Ausloos, K; Chinnakotla, S; Davis, GL; Klintmalm, GB; Ramsay, M; Rogers, L; Saadeh, S | 1 |
2 review(s) available for bosentan anhydrous and Cirrhosis, Liver
| Article | Year |
|---|---|
Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Cholestasis; Fatty Liver; Humans; Liver Cirrhosis; Methotrexate; Quantitative Structure-Activity Relationship; Sulfonamides; Valproic Acid | 2015 |
Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Liver Transplantation; Pulmonary Circulation; Sulfonamides; Treatment Outcome | 2006 |
10 other study(ies) available for bosentan anhydrous and Cirrhosis, Liver
| Article | Year |
|---|---|
Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Topics: Antihypertensive Agents; Bosentan; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Echocardiography; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Treatment Outcome | 2015 |
Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.
Topics: Animals; Bosentan; Collateral Circulation; Cyclooxygenase 2; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Hypertension, Portal; Liver Cirrhosis; Male; Neovascularization, Pathologic; Nitric Oxide Synthase Type II; Phenylpropionates; Phosphoproteins; Portal Pressure; Proto-Oncogene Proteins c-akt; Pyridazines; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice.
Topics: Acute Kidney Injury; Animals; Antihypertensive Agents; Bosentan; Drug Synergism; Endothelin-1; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Receptors, Angiotensin; Sulfonamides; Ureteral Obstruction; Valsartan | 2016 |
Renal failure in cirrhosis.
Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Pyridines; Renal Insufficiency; Sulfonamides; Tetrazoles | 2010 |
Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression; Hemodynamics; Hepatic Stellate Cells; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Oligopeptides; Peptides, Cyclic; Piperidines; Portal Pressure; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Regional Blood Flow; Sulfonamides | 2010 |
Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
Topics: Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Liver Cirrhosis; Liver Transplantation; Middle Aged; Platelet Aggregation Inhibitors; Sulfonamides; Time Factors | 2004 |
Endothelin-receptor antagonist treatment of portopulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Female; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Middle Aged; Sulfonamides | 2004 |
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Sulfonamides; Treatment Outcome | 2006 |
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
Topics: Adult; Antihypertensive Agents; Bosentan; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Male; Renal Insufficiency; Sulfonamides; Treatment Outcome | 2006 |
The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Diltiazem; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents | 2007 |